BREO ELLIPTA
ICSLABA DPI
Fluticasone furoate / Vilanterol · GlaxoSmithKline
Active Medication & Mechanism
- Fluticasone furoate ICS50 mcg, 100 mcg, or 200 mcg per blister
Synthetic corticosteroid with enhanced glucocorticoid receptor affinity. Provides potent anti-inflammatory activity with once-daily dosing due to prolonged lung tissue retention.
- Vilanterol trifenatate LABA25 mcg per blister
Long-acting beta2-adrenergic agonist. Provides sustained bronchodilation for ≥24 hours with once-daily dosing.
FDA-Approved Dosing — Strength × Indication
Strength Regimen AsthmaCOPD
100/25 mcg
1 inhalation once daily → 100/25 mcg
FDA Approved
Maintenance treatment of asthma in adults.
FDA Approved
Once-daily maintenance treatment of airflow obstruction in COPD. Also reduces COPD exacerbations in patients with a history of exacerbations.
200/25 mcg
1 inhalation once daily → 200/25 mcg
FDA Approved
For adults requiring a higher inhaled corticosteroid dose. Maximum recommended asthma dose.
Not Approved
The 200/25 mcg strength is NOT indicated for COPD. Only 100/25 mcg is approved for COPD.
All regimens shown apply to adults (≥18 years) unless otherwise noted · verify against current labelling
100/25 mcg 1 inhalation once daily → 100/25 mcg
Asthma FDA Approved
Maintenance treatment of asthma in adults.
COPD FDA Approved
Once-daily maintenance treatment of airflow obstruction in COPD. Also reduces COPD exacerbations in patients with a history of exacerbations.
200/25 mcg 1 inhalation once daily → 200/25 mcg
Asthma FDA Approved
For adults requiring a higher inhaled corticosteroid dose. Maximum recommended asthma dose.
COPD Not Approved
The 200/25 mcg strength is NOT indicated for COPD. Only 100/25 mcg is approved for COPD.
All regimens shown apply to adults (≥18 years) unless otherwise noted · verify against current labelling
Not a rescue inhaler. Not for acute bronchospasm. Use a SABA.